CN100418573C - External Chinese medicine for treating ankylosing spondylitis - Google Patents
External Chinese medicine for treating ankylosing spondylitis Download PDFInfo
- Publication number
- CN100418573C CN100418573C CNB2005100478777A CN200510047877A CN100418573C CN 100418573 C CN100418573 C CN 100418573C CN B2005100478777 A CNB2005100478777 A CN B2005100478777A CN 200510047877 A CN200510047877 A CN 200510047877A CN 100418573 C CN100418573 C CN 100418573C
- Authority
- CN
- China
- Prior art keywords
- joint
- ankylosing spondylitis
- chinese medicine
- pain
- treatment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The present invention relates to a Chinese medicine for external application for curing ankylosing spondylitis. It is made up by mixing the following 8 Chinese medicinal materials: eucommia bark 40-50g. aconite main tuber 20-30g. turmeric 20-30g, dried ginger 20-30g, orient vine 20-30g, speranskia/balsam 20-30g, arisaema root 10-20g and dragon's blood 0.5-1g.
Description
Technical field
The present invention belongs to Chinese medicine preparation.
Background technology
Ankylosing spondylitis is a kind of based on the infringement spinal column, the chronic progressive external immunological diseases that can involve extremity and whole body, and its sickness rate accounts for 0.5% of population, the morbidity crowd age is lower, the course of disease is very long, and the obvious genetic family history is arranged, and therapeutic effect is poor, the disability rate height, along with the progress of detection means, the number of making a definite diagnosis of this disease is ascendant trend year by year, and morbidity population increases gradually, be common clinical, frequently-occurring disease.
Medical circle was advanced unremitting effort both at home and abroad, by a large amount of experimentatioies, proposed the molecular simulation theory, and, thought that the pathogenesis of ankylosing spondylitis is because behind the human infection pathogenic entero becteria through clinical verification, bring out body by common molecular structure and produce immunoreation with HLA-B27, the antibody that produces at first arrives and closes on sacroiliac joint and lumbar vertebra position, antigen antibody reaction takes place, the attachment end of attack joints tendon, inflammation of sacroiliac joint appears, occur erythrocyte sedimentation rate in the blood and speed interleukin, TNF, CRP, immunoglobulin raises, and complement C3 reduces, can detect the HLA-B27 positive, sacroiliac joint X sheet or CT show that articular surface corrodes, sclerosis, arthrostenosis, even joint fusion, tetanic, spinal column is the ring sample and becomes, when antibody produces more for a long time, then enter blood circulation, cause arthritis reaction on every side.Use NSAID (non-steroidal anti-inflammatory drug), hormone, immunosuppressant and oral formulations treatment primary disease at present, exist the expense height, curative effect is dissatisfied, side effect is big, the deficiency that the course of treatment is long, the patient of clinicist and ankylosing spondylitis presses for employing curative effect height, side effect is little, can obviously palliate the agonizing sufferings effective Therapeutic Method of disease controlling.
Ankylosing spondylitis motherland medical science belongs to " arthromyodynia " category, motherland's medical science is thought because the human body weakened defensive QI, striae of the skin and muscles being loose, wind, cold, damp and hot heresy, enter human body in an opponent's defence, if human righteousness's weakness can not in time be got rid of evils and be gone out, with the passing of time pathogen keeps muscles and bones, muscle, the joint, the impatency venation, cause QI-blood circulation smooth due to.The eighties, Jiao established one's virtue professor according to its clinical manifestation, with its return for " Wang numbness " category, medical circles admit widely in now having obtained.Qi Yan is by analyzing the primary disease age of onset, sex, the relations of site of pathological change and kidney etc. are pointed out deficiency of kidney-essence, deficiency of qi and blood, passages through which vital energy circulates lose supports, multiple because of exopathogen invasion and attack or wound, overstrain causes governor vessel inanition or stasis etc. to be the pathogeny of primary disease, and its pathogenic characteristic of lay special stress on one weakened body resistance be this, even the wet sign of wind and cold is arranged, also mostly be wind syndrome due to blood-deficiency, cold manifestation due to yang deficiency, insufficiency of the spleen resulting in production of dampness, be not quite similar with general numbness disease, Zhu Jianhuas etc. think that the root of primary disease is that kidney is superintended and directed inanition, and Wei Yang is empty, and the heresy that wind and cold is damp and hot is taken advantage of a weak point in opponent's defence and attacked, go deep into the joint spinal cord, because healthy energy is lost empty, pathogen lies prostrate deeply in interior, and phlegm-turbidity and blood stasis blood produces mutually, the harmony governor vessel that stagnates, heresy is just obscured, and goes into face as oil, deadlocked being difficult to resolve, finally cause rigid spine, distortion etc.Xu Chenglin then is summarised as caused by liver and kidney deficiency with it, and governor vessel loses supports; Insufficiency of vital energy and blood, the resistance muscles and bones of becoming silted up, the cold coagulation governor vessel, and just inquire into two aspects from internal and external reasons and heresy.High with the turbid importance of heresy in primary disease is fallen ill of lay special stress on expectorant such as moral, point out that the interior QI-blood circulation of patient's body is not normal, give birth in expectorant is turbid, flow in meridians, lie prostrate in governor vessel a then sick kyphosis; Flow in joint muscle arteries and veins retardance qi and blood circulation, stagnation of QI and blood may bring about pain.Fu Xinli reduces the etiology and pathogenesis of primary disease: suffer from a deficiency of the kidney and superintend and direct empty inherent basis for the disease generation; Being invaded by exogenous pathogen, inside and outside combined pathogens are the external conditions that disease forms, and the evil numbness of suffering from a deficiency of the kidney is the most basic pathological process.
Summary of the invention:
The present invention is exactly at the problems referred to above, and a kind of effective external Chinese medicine of ankylosing spondylitis for the treatment of is provided.
The present invention adopts following technical scheme: Cortex Eucommiae 40-50g, Radix Aconiti 20-30g, Rhizoma Curcumae Longae 20-30g, Rhizoma Zingiberis 20-30g, Caulis Sinomenii 20-30g, Herba speranskiae tuberculatae 20-30g, Rhizoma Arisaematis 10-20g, Sanguis Draxonis 0.5-1g are made after mixing.
Beneficial effect of the present invention:
Based on the understanding of motherland's medical science to this disease, having established the kidney invigorating superintends and directs by force, dispelling cold and removing dampness, phlegm reduction of blood circulation promoting, the eliminating obstruction to activate collaterals method is treated this disease, and the screening active drug is formed effective prescription on the basis of having carried out a large amount of clinical applications, developed the unguentum of topical administration, and the time of having used 4 years carried out the clinical contrast observation of the treatment ankylosing spondylitis of this medicine, confirm that this prescription has the kidney invigorating and superintends and directs by force, dispelling cold and removing dampness, phlegm reduction of blood circulation promoting, the effect of eliminating obstruction to activate collaterals, alleviating pain in the short period of time, disease controlling, determined curative effect, side effect is slight, shows according to further doing animal experiment: (1) this medicine has the good restraining effect to the constitutional foot swelling of adjuvant arthritis rat; (2) this medicine has the good restraining effect to the Secondary cases foot swelling of adjuvant arthritis rats.(3) this medicine can reduce the content of adjuvant arthritis rats serum TNF-a, IL-1 β, IL-2, CRP; (4) visible this medicine can suppress the inflammatory cell infiltration of adjuvant arthritis rats synovial tissue under the fiber Electronic Speculum.Selection of clinical 76 routine patients are divided into external Chinese drug-treated group of the present invention, diclofenac emulsion group at random.The result shows the sick cold-dampness type patient of external treatment by Chinese herbs numbness of the present invention 34 examples, relatively preceding with treatment, the swelling integration reduces, significant difference (P＜0.05=, with relatively swelling integration reduction of matched group, (P＜0.05=illustrates external Chinese medicine of the present invention in arthralgia, the arthroncus of treatment ankylosing spondylitis and improve and significant curative effect is arranged aspect the function of joint to significant difference, and treatment arthroncus curative effect is better than the diclofenac emulsion group.Conclusion: external Chinese medicine of the present invention has therapeutical effect preferably in clinical treatment cold-dampness type ankylosing spondylitis.
The specific embodiment:
Embodiment 1:
The present invention is Cortex Eucommiae 50g, Radix Aconiti 30g, and Rhizoma Curcumae Longae 30g, Rhizoma Zingiberis 30g, Caulis Sinomenii 30g, Herba speranskiae tuberculatae 30g, Rhizoma Arisaematis 20g Sanguis Draxonis 0.5g makes after mixing.
Embodiment 2:
The present invention is Cortex Eucommiae 45g, Radix Aconiti 25g, and Rhizoma Curcumae Longae 25g, Rhizoma Zingiberis 25g, Caulis Sinomenii 25g, Herba speranskiae tuberculatae 25g, Rhizoma Arisaematis 15g Sanguis Draxonis 0.3g makes after mixing.
Usage
External spreads on spinal column outward, extremities joint pain swelling position.Stick once a day, a week is a course of treatment, but 4 courses of treatment of logotype.
Preparation method (being routine fashion)
1. get the Cortex Eucommiae, Rhizoma Curcumae Longae, Radix Aconiti, Rhizoma Zingiberis, Herba speranskiae tuberculatae, Caulis Sinomenii, Rhizoma Arisaematis seven flavor medicine material, by ratio 5: 3: 3: 3: 3: 3: 2 inserted in the extracting cylinder, with the alcohol reflux of 75%--90% three times, extraction time is three hours for the first time, and extraction time is two hours for the second time, and extraction time is one hour for the third time, the consumption of used solvent is 1.5 times of medical material, merge extractive liquid,, being concentrated into relative density is that 1.25-1.35, mensuration temperature are 50-60 ℃ extractum, it is standby to weigh.It is standby that Sanguis Draxonis powder is broken into 100-200 order fine powder.
2. get Sanguis Draxonis powder and mix with Chinese medical concrete, it is even that other gets 2.0-3.0 times of substrate (rubber composition substrate, thermoplastic rubber's substrate) and medicament mixed, makes the unguentum raw material; After sieving with 60--100 order stainless steel mesh, gluing is cut, and makes the plaster of necessary requirement.
3. paste containing amount is greater than 5.0g/100cm
2
4. specification: 7cm * 5cm; 7cm * 10cm; 10cm * 20cm; 10cm * 30cm.
Clinical
1. clinical data
1.1 case is selected: in year January in February, 2002 to 2004, my section uses external Chinese medicine of the present invention to the proper patients with ankylosing spondylitis of 76 examples and carries out clinical research.76 routine patients are divided into two groups at random, wherein male 71 examples, and women 5 examples, the age is in 18-65 year.38 examples are organized in treatment, wherein male 35 examples, and women 3 examples, the age minimum is 19 years old, is 48 years old to the maximum, average out to 32.94 ± 6.67 years old; The course of disease is the shortest 1 year, and is the longest 12 years, average 5.40 ± 3.35 years, loses and visits 4 examples.Matched group 38 examples, wherein male 36 examples, women 2 examples, the age minimum is 18 years old, is 55 years old to the maximum, average out to 32.41 ± 9.04 years old; The course of disease is the shortest 1 year, and is the longest 12 years, average 4.47 ± 3.34 years, loses and visits 3 examples.Two groups of patients' sex, age, the course of disease are learned processing by statistics, and there was no significant difference (P＞0.05) has comparability.
1.2 inclusion criteria: meet the clinical criteria (adopting the New York standard of revision in 1984) of doctor trained in Western medicine ankylosing spondylitis and the dialectical standard of traditional Chinese medical science cold-dampness type: waist, extremities joint cold type of pain are weighing, local fear of cold, color of the leather is not red, that touches is not hot, pain increase in intensity under coldness, pain alleviated while getting warmth, dimly pale tongue, the greasy in vain or whiten of tongue, stringy and tense pulse or string are slow.
1.3 syndrome integration standard
1.3.1. arthralgia:
0 minute: the painful or pain disappearance in joint;
2 minutes: pain was light, can stand, or pain when fatigue or Changes in weather only, do not influence work substantially;
4 minutes: pain was heavier, and work and rest all are affected;
6 minutes: pain was serious, was difficult to stand, and had a strong impact on work and rest, need be used analgesic drug product.
1.3.2. arthroncus
0 minute: the joint did not have swollen or swelling disappears;
2 minutes: the joint was slightly swollen, and the bone mark in joint is high-visible;
4 minutes: the joint moderate was swollen, and skin texture disappears substantially, and the bone sign is not obvious;
6 minutes: joint severe was swollen, or hydrarthrosis is arranged, arthroncus very, tight, the bone marks obliterated of skin.
1.3.3. articular pain
0 minute: the joint does not have tenderness or tenderness disappears;
1 minute: mild tenderness, patient claimed to have pain;
2 minutes: the moderate tenderness, patient Shang Neng stands, the discomfort etc. of frowning;
3 minutes: severe tenderness, pain can not be touched, patient's pain is unbearably when extruding the joint.
1.3.4. function of joint
0 minute: joint motion was normal;
1 minute: joint motion was slightly limited, and range of motion reduces≤1/3
2 minutes: joint motion was obviously limited, and range of motion reduces＞1/3
3 minutes: joint motion was seriously limited, and joint motion reduces 〉=1/2 even stiff.
1.3.5. joint cold type of pain
0 minute: the joint did not have cold type of pain
1 minute: the slight cold type of pain in joint, the patient claims slightly to be afraid of cold;
2 minutes: joint moderate cold type of pain, patient Shang Neng stands, and needs warming;
3 minutes: joint severe cold type of pain, patient was impatient at, and needs heating system.
1.4 severity extent standard
Slightly: symptom integral≤7 minute;
Moderate: symptom integral 〉=8 minute ,≤18 minutes;
Severe: symptom integral 〉=19 minute.
2. observation index
Clinical symptoms: the integration that respectively writes down arthralgia, arthroncus, articular pain, function of joint, joint cold type of pain etc. before the administration and after the administration the 1st, 2,3,4 weeks; Physical and chemical index: administration is forward and backward respectively chemically examines erythrocyte sedimentation rate, c reactive protein and a safety indexes (routine blood test, routine urinalysis, just routine, liver function, renal function, electrocardiogram); Untoward reaction observation:, itemized record with the relevant untoward reaction of curative possibility.
3. medication
The treatment group: external Chinese medicine of the present invention (make powder, before the administration with 38% ethanol or rice vinegar furnishing paste) by the Drug Manufacturing Room of the court, 20g at every turn, 1 external application every day, placebo (being provided by the Drug Manufacturing Room of the court) 1g is coated with outward for per 8 hours 1 time; Matched group: Vitalin Emulgel (the 1% diclofenac diethylammonium salt of being produced by the Novartis company limited), each 1g is coated with placebo (being provided by the Drug Manufacturing Room of the court) 20g, 1 external application every day outward per 8 hours 1 time.Treatment group and matched group were a course of treatment with 1 month all.
4. curative effect determinate standard
Produce effects: cardinal symptom, the whole improvement rate of sign 〉=75%, the normal or obviously improvement of erythrocyte sedimentation rate and c reactive protein; Progressive: cardinal symptom, the whole improvement rate of sign 〉=50%, erythrocyte sedimentation rate and c reactive protein have improvement; Effectively: cardinal symptom, the whole improvement rate of sign 〉=30%, erythrocyte sedimentation rate and c reactive protein have improvement or do not have improvement; Invalid: cardinal symptom, the whole improvement rate of sign＜30%, erythrocyte sedimentation rate and c reactive protein do not have improvement.
Annotate: cardinal symptom, sign are meant 2 of articular pain number, arthroncus numbers etc.Whole improvement rate be meant above 2 indexs improve percentage rate [(value before the treatment-treatment back value)/treat preceding value * 100%] addition after ask its meansigma methods.
5. statistical method
Adopt the SPSS10.0 statistical packages to add up, measurement data represents to adopt the T of independent sample or the T of paired sample to check with X ± S, the enumeration data employing *
2Check.
The result
1. general curative effect (table 1)
Table 1 external Chinese medicine of the present invention general curative effect
As seen from Table 1, general curative effect and matched group are more basic identical, and difference does not have significance (P＞0.05)
2. the comparison (table 2) of symptom and lab index before and after the treatment
The comparison of symptom and lab index integration before and after the table 2 liang group patient treatment (x ± s)
△ and preceding relatively P＜0.05 of treatment, ★ and matched group be P＞0.05 relatively, and ★ ★ and matched group be P＜0.05 relatively
3. onset time
Table 3 external Chinese medicine of the present invention is to the ankylosing spondylitis arthralgia comparison of onset time (x ± s)
△ and matched group be P＜0.05 relatively
In sum, external treatment by Chinese herbs ankylosing spondylitis cold-dampness type patient 34 examples of the present invention, its total effective rate is 97.1%, to clinical symptoms such as arthralgia, arthroncus, articular pain, function of joint, joint cold type of pain and lab index erythrocyte sedimentation rate, the c reactive protein (P＜0.05=that all is significantly improved.In lenitive onset time and improve aspect the cold type of pain symptom of joint, significant difference (P＜0.05=is relatively arranged with matched group.Point out external Chinese medicine of the present invention therapeutical effect preferably to be arranged by local penetration.Untoward reaction does not appear in the observation.
Claims (2)
1. an external Chinese medicine for the treatment of ankylosing spondylitis is characterized in that Cortex Eucommiae 40-50g, Radix Aconiti 20-30g, Rhizoma Curcumae Longae 20-30g, Rhizoma Zingiberis 20-30g, Caulis Sinomenii 20-30g, Herba speranskiae tuberculatae 20-30g, Rhizoma Arisaematis 10-20g, Sanguis Draxonis 0.5-1g are made after mixing.
2. a kind of external Chinese medicine for the treatment of ankylosing spondylitis according to claim 1 is characterized in that Cortex Eucommiae 50g, Radix Aconiti 30g, Rhizoma Curcumae Longae 30g, Rhizoma Zingiberis 30g, Caulis Sinomenii 30g, Herba speranskiae tuberculatae 30g, Rhizoma Arisaematis 20g, Sanguis Draxonis 0.5g are made after mixing.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2005100478777A CN100418573C (en) | 2005-11-30 | 2005-11-30 | External Chinese medicine for treating ankylosing spondylitis |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2005100478777A CN100418573C (en) | 2005-11-30 | 2005-11-30 | External Chinese medicine for treating ankylosing spondylitis |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1977963A CN1977963A (en) | 2007-06-13 |
| CN100418573C true CN100418573C (en) | 2008-09-17 |
Family
ID=38129383
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB2005100478777A Expired - Fee Related CN100418573C (en) | 2005-11-30 | 2005-11-30 | External Chinese medicine for treating ankylosing spondylitis |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN100418573C (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106334123A (en) * | 2016-11-15 | 2017-01-18 | 黄兆龙 | Traditional Chinese medicine decoction for treating ankylosing spondylitis and preparation method thereof |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1569100A (en) * | 2003-12-26 | 2005-01-26 | 吴英萍 | Medicine for treating rheumatoid arthritis and ankylosing spondylitis and its preparation method |
-
2005
- 2005-11-30 CN CNB2005100478777A patent/CN100418573C/en not_active Expired - Fee Related
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1569100A (en) * | 2003-12-26 | 2005-01-26 | 吴英萍 | Medicine for treating rheumatoid arthritis and ankylosing spondylitis and its preparation method |
Non-Patent Citations (1)
| Title |
|---|
| 祛痹通络膏治疗寒湿型强直性脊柱炎疗效观察. 薛书燕等.辽宁中医杂志，第31卷第9期. 2004 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1977963A (en) | 2007-06-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102178800B (en) | Chinese medicine composition for treating rheumatoid arthritis and preparation method thereof | |
| CN1803187A (en) | Chinese herbal medicine for treating lumbar intervertebral disk protrusion and hyperosteogeny | |
| CN108310320A (en) | A kind of externally applied drug and preparation method thereof for treating gout | |
| CN106266463A (en) | A kind of Chinese medicine composition for treating hyperuricemia and application thereof | |
| CN1628768A (en) | Medicine for treating gout affection and its symptoms | |
| CN102188496B (en) | Chinese medicine for treating ankylosing spondylitis and preparation method thereof | |
| CN101040949B (en) | Medicine compound for creating rheumatism and rheumatoid arthritis and the preparing method and application | |
| CN100418573C (en) | External Chinese medicine for treating ankylosing spondylitis | |
| CN105106498A (en) | Traditional Chinese medicine composition for treating diabetic foot | |
| CN103920044A (en) | Medicine for treating urethral calculus and preparation method thereof | |
| CN1876088A (en) | A medicine for treating chronic prostatitis and preparation method thereof | |
| CN103239565B (en) | Wind-dispelling and spur-removing soup for treating arthralgia and preparation method of soup | |
| CN1248727C (en) | Insensitive impediment capsule and its manufacturing method | |
| CN100441208C (en) | Bolus for treating rheumatic or rheumatoid arthritis and its preparation method | |
| CN101375955B (en) | Sperm-passing formulation for treating non-ejaculation symptom and preparation method thereof | |
| CN108619427A (en) | A kind of pain deacidification medicinal herb tea of dispelling of prophylactic treatment urarthritis | |
| CN103520638B (en) | A kind of Traditional Chinese medicine compound composition for the treatment of prostate hyperplasia and preparation method thereof and application thereof | |
| CN1057925C (en) | Pill for treating hepatitis and ascites due to liven cirrhosis, and method for preparing same | |
| CN101361955B (en) | Traditional Chinese medicine combination for treating rheumatism | |
| CN107050333B (en) | Granules for treating ankylosing spondylitis | |
| CN102225130B (en) | Traditional Chinese medicine compound for treating rheumatoid arthritis and preparation method thereof | |
| CN101757369A (en) | Medicine composition for treating acute goutry arthritis and preparation process thereof | |
| CN106728060A (en) | It is a kind of to treat externally applied ointment of rheumatism and preparation method thereof | |
| CN105688096A (en) | Traditional Chinese medicine composition for treating gout | |
| CN102716262B (en) | Traditional Chinese medicine formula for curing ankylosing spondylitis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C17 | Cessation of patent right | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20080917 Termination date: 20101130 |